Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 28 Oct, 18:06 UTC

Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults with type 2 diabetes. Retatrutide is a peptide designed to activate three metabolic targets versus just one hit by Ozempic. The post Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic…

science

Sources

• T2Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes TrialFierce Biotech / Fierce Healthcare / MedCity / GEN28 Oct, 18:06